Genmab A/S (NASDAQ:GMAB) Hits New 1-Year Low at $24.36

Genmab A/S (NASDAQ:GMAB)’s share price reached a new 52-week low during trading on Monday . The company traded as low as $24.36 and last traded at $24.36, with a volume of 80559 shares. The stock had previously closed at $25.53.

Analyst Upgrades and Downgrades

GMAB has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Friday. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. Morgan Stanley reiterated an “equal weight” rating and issued a $31.00 target price on shares of Genmab A/S in a research report on Wednesday, September 11th. BTIG Research increased their target price on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Finally, Truist Financial decreased their price target on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, September 9th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Genmab A/S currently has a consensus rating of “Hold” and an average target price of $45.20.

Genmab A/S Stock Performance

The business has a 50 day simple moving average of $27.27 and a 200-day simple moving average of $27.98. The firm has a market cap of $16.02 billion, a price-to-earnings ratio of 21.28, a P/E/G ratio of 0.81 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. The company had revenue of $779.50 million during the quarter, compared to analysts’ expectations of $734.60 million. As a group, research analysts anticipate that Genmab A/S will post 1.27 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of GMAB. Russell Investments Group Ltd. lifted its position in shares of Genmab A/S by 137.7% during the first quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after acquiring an additional 544 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Genmab A/S by 194.0% in the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock valued at $34,000 after acquiring an additional 749 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Genmab A/S during the 1st quarter valued at about $43,000. Barometer Capital Management Inc. purchased a new stake in Genmab A/S in the fourth quarter valued at approximately $121,000. Finally, Headlands Technologies LLC boosted its holdings in shares of Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock worth $129,000 after purchasing an additional 4,853 shares in the last quarter. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.